Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Presenter: Muthia Vaduganathan

March 22, 2016

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

Presentation

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Presenter: C.W. Lee

October 10, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

Presentation

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Presenter: A. P. Amin

March 26, 2013

Presentation

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Presenter: Marco Valgimigli

January 16, 2013

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Presentation

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Presenter: B-K Kim

September 19, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ISET 2012

The Value of Dual Antiplatelet Therapy During and After Endovascular Procedures: Results of a Randomized Trial - The MIRROR Study

Presenter: Gunnar Tepe

January 17, 2012

Advertisement

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

The Value of Dual Antiplatelet Therapy During and After Endovascular Procedures: Results of a Randomized Trial - The MIRROR Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content